Original news and analysis on international IP policy
Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it.
The World Trade Organization council on intellectual property rights will hold the first of its three annual meetings next week. The now-usual item on IP and innovation is joined by a discussion topic on IP and the public interest. Separately, the WTO least developed countries group has put forward a request that developed countries fully implement their technology transfer requirements under the WTO rules. The council meeting will be preceded by a high-level trilateral meeting of the WTO, World Health Organization and World Intellectual Property Organization.
CARB-X , a global private-public partnership for research on antimicrobial resistance, this week announced its 2018 rounds of funding for research on "antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria."
Some international organisations are having to gear up to address proposed cuts to their budgets announced this month by the United States, in many cases the major funder. Geneva-based health agencies this week responded that they are counting on the US not to make significant cuts.
The steady increase in innovations relating to new digital technologies, in particular technologies using artificial intelligence, is matched by an upward patenting trend. The European Patent Office recently issued a study on the subject and is preparing a conference in May, while the World Intellectual Property Organization is working on its own in-depth study. However, the current patent system might not be ready for artificial intelligence-related inventions, according to a global standards-setting body.
The Electronic Frontier Foundation launched a project last year to measure progress in artificial intelligence innovations and understand the legal, political, and technical issues potentially raised by those inventions. Some eight months later, the project has tracked rapid progress of those technologies, in particular in machine learning. According to the foundation, patents might be hampering the progress of artificial intelligence, and with the risk of patent trolls claiming rights on patents on machine learning systems.
NEW YORK -- Technology is moving so fast it could cause harm to humans even as it brings remarkable advances unless governments act, an Israeli professor and visionary thinker told a gathering of government and United Nations representatives here last week. A hint? In the next five years we are all going to be cyborgs. In fact most of us already are.
The United States Patent and Trademark Office (USPTO) is predicting a slight decline in some patent filings for 2018 and 2019, including through the international Patent Cooperation Treaty (PCT) managed by the World Intellectual Property Organization. Trademarks, meanwhile, will likely see slowing growth.
The chair of the World Intellectual Property Organization committee on copyright issued revised language last week on core articles of a potential treaty protecting broadcasting organisations against signal piracy. The document shows a trimmer set of different proposals by countries during informal discussions to address issues such as what the treaty should protect, which rights should be granted, and who should benefit from such rights.
In a recent trademark opposition, the Opposition Board of the Japan Patent Office (JPO) decided to overrule the opposition against TM Registration no. 5951823 for word mark “TÉ CON MIEL” designating tea in class 30 due to distinctiveness of the mark among relevant Japanese consumers.
While the Trump administration has taken aim overall at US contributions to international organisations since taking office last year, the budget proposal it put forward last week would roughly maintain last year's lower levels for a range of Geneva-based agencies without making further cuts. Others did not fare as well.
Pharmaceutical company Gilead has made headlines in recent years for offering the hepatitis C drug Sovaldi that has helped many patients. And for the fact that it came with an eye-popping price tag. Perhaps in a sign of the times, Gilead this month won an open-and-shut case against a squatter on the domain name "sovaldi.eu," that was offering lower-priced generic versions of Sovaldi, including through links to "buyers' clubs" organised to obtain medicines more affordably. The website was called, "SOVALDI. The life-saving cure for Hepatitis C which nobody can afford." Was it a little act of rebellion, or just another internet opportunist?